Patents by Inventor Shaomeng Wang

Shaomeng Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MDM2 protein degraders
    Patent number: 12637473
    Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1??I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: May 26, 2026
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
  • Compounds and Compositions as VHL Ligands and STAT3 Degraders Uses Thereof
    Publication number: 20260108613
    Abstract: Described herein are compounds or conjugates of Formula I or II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as VHL-binding agents or bifunctional degraders for degrading certain proteins (e.g., STAT3)).
    Type: Application
    Filed: December 19, 2025
    Publication date: April 23, 2026
    Inventors: Shaomeng Wang, Haibin Zhou, Dimin Wu, Ranjan Kumar Acharyya, Longchuan Bai, Donna McEachern, Hoda Metwally, Mi Wang, Paul Kirchhoff, Jelena Tosovic
  • COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF
    Publication number: 20260092071
    Abstract: Described herein are compounds of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders).
    Type: Application
    Filed: September 22, 2023
    Publication date: April 2, 2026
    Inventors: Shaomeng Wang, Lingying Leng, Lin Yang, Wenbin Tu, Liyue Huang, Mi Wang, Wei Jiang, Paul Kirchhoff, Guozhang Xu, Zhenwu Li, Lalgudi Harikrishnan, E. Scott Priestley, Jelena Tosovic, Jeanne Stuckey
  • STAT3 protein degraders
    Patent number: 12570679
    Abstract: The present disclosure provides compounds represented by Formulae I and IV: wherein R1a, R1b, R2a, R2b, A, E, QD, and QE are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are degraders of STAT3. Compounds of Formula IV are inhibitors of STAT3. STAT3 degraders and inhibitors are useful for the treatment of cancer and other diseases.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: March 10, 2026
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu
  • TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20260028354
    Abstract: Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as estrogen receptor degraders).
    Type: Application
    Filed: July 12, 2023
    Publication date: January 29, 2026
    Inventors: Guozhang Xu, Zhixiang Chen, Rohan Rej, Ranjan Kumar Acharyya, Dimin Wu, Ms. Mingliang Wang, Biao Hu, Jianfeng Lu, Zhenwu Li, E. Scott Priestley, Shaomeng Wang
  • Small molecule STAT protein degraders
    Patent number: 12522623
    Abstract: The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R3a, R4, A, E1, E2, M, and Q are as set forth in the specification. Compounds of Formula (I) are STAT protein degraders and thus are useful for the treatment of cancer and other diseases.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: January 13, 2026
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Haibin Zhou, Renqi Xu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Chao-Yie Yang
  • INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20260007681
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
    Type: Application
    Filed: July 12, 2023
    Publication date: January 8, 2026
    Inventors: Rohan Rej, Zhixiang Chen, Mingliang Wang, Dimin Wu, Guozhang Xu, Ranjan Kumar Acharyya, Biao Hu, Jianfeng Lu, Shaomeng Wang
  • CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20260000676
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
    Type: Application
    Filed: July 12, 2023
    Publication date: January 1, 2026
    Inventors: Guozhang Xu, Ranjan Kumar Acharyya, Rohan Rej, Zhixiang Chen, Biao Hu, Jianfeng Lu, Shaomeng Wang
  • IKZF2 DEGRADERS AND USES THEREOF
    Publication number: 20250215012
    Abstract: Described herein are compounds of Formulae I? and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).
    Type: Application
    Filed: March 24, 2023
    Publication date: July 3, 2025
    Inventors: Zhixiang Chen, Rohan Rej, Xuqing Zhang, Longchuan Bai, Paul Kirchhoff, Shaomeng Wang
  • CEREBLON LIGANDS AND USES THEREOF
    Publication number: 20250195484
    Abstract: Described herein are compounds or conjugates of Formula II and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: March 24, 2023
    Publication date: June 19, 2025
    Inventors: Haibin Zhou, Dimin Wu, Changwei Wang, Mi Wang, Shaomeng Wang, Rohan Rej, Zhixiang Chen, Ranjan Kumar Acharyya, Longchuan Bai, Paul Kirchhoff, Guozhang Xu, Xuqing Zhang, Zhenwu Li, Biao Hu, Jianfeng Lu
  • Macrocyclic fused pyrazoles as Mcl-1 inhibitors
    Patent number: 12319703
    Abstract: Provided are compounds represented by Formula IA: (IA), and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, L1, L2, L3, X, A, B and C are as defined as set forth in the specification. Also provided compounds of Formula IA for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: June 3, 2025
    Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., REGENTS OF THE UNIVERSITY OF MICHIGAN, ASCENTAGE PHARMA GROUP CORP LIMITED
    Inventors: Guozhi Tang, Dongbo Li, Liugen Li, Xianchan Zha, Wenming Chen, Shaomeng Wang, Chao-Yie Yang
  • IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF
    Publication number: 20250034162
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: September 17, 2024
    Publication date: January 30, 2025
    Inventors: Shaomeng Wang, Rohan Rej, Changwei Wang, Mi Wang, Jianfeng Lu, Chao-Yie Yang, Ester Fernandez-Salas, Jeanne Stuckey
  • Imidazopyrimidines as EED inhibitors and the use thereof
    Patent number: 12145944
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are EED inhibitors. EED inhibitors are useful for the treatment of cancer and other diseases.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: November 19, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Rohan Rej, Changwei Wang, Mi Wang, Jianfeng Lu, Chao-Yie Yang, Ester Fernandez-Salas, Jeanne Stuckey
  • Small molecule DCN1 inhibitors and therapeutic methods using the same
    Patent number: 12012467
    Abstract: Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: June 18, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Haibin Zhou, Jianfeng Lu, Liu Liu, Yi Sun, Denzil Bernard
  • SMALL MOLECULE DEGRADERS OF ESTROGEN RECEPTOR WITH CEREBLON LIGANDS
    Publication number: 20240190880
    Abstract: The present disclosure relates to compounds of Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X, J, Y, Z, n, and B 1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating preventing a condition or disorder responsive to the degradation of estrogen receptor protein (e.g., cancer).
    Type: Application
    Filed: March 4, 2022
    Publication date: June 13, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Rohan Rej, Dimin Wu, Jianfeng Lu, Biao Hu, Mingliang Wang, Ranjan Kumar Acharyya
  • SMALL MOLECULE DEGRADERS OF ANDROGEN RECEPTOR
    Publication number: 20240190874
    Abstract: The present disclosure provides compounds of Formula (I): and the salts or solvates thereof, wherein A1, B1, L, and X2 are as defined in the specification. The present disclosure also relates to uses of the compounds, e.g., as androgen receptor degraders useful for the treatment of diseases (e.g., cancer).
    Type: Application
    Filed: March 3, 2022
    Publication date: June 13, 2024
    Inventors: Shaomeng Wang, Lijie Zhao, Xin Han, Weiguo Xiang
  • Cereblon Ligands
    Publication number: 20240166647
    Abstract: The present disclosure provides compounds of Formula (I), wherein A, A1, A2, A3, R3, Z and Z1 are as defined in the specification, and the salts and solvates thereof. The present disclosure also relates to uses of the compounds as cereblon (CRBN) ubiquitination inhibitors, as synthetic intermediates that can be used to prepare PROTAC molecules, or as PROTAC molecules. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing cancer and other diseases.
    Type: Application
    Filed: March 3, 2022
    Publication date: May 23, 2024
    Inventors: Shaomeng Wang, Tianfeng Xu, Dimin Wu, Zhixiang Chen, Xin Han, Weiguo Xiang, Rohan Rej, Angelo Aguilar, Longchuan Bai
  • Small Molecule Degraders of CBP/p300 Proteins
    Publication number: 20240150360
    Abstract: The present disclosure relates to compounds of Formula (I), and the pharmaceutically A—(CH2)m—X—Y—Z—B1??I, acceptable salts and solvates thereof, wherein A, m, X, Y, Z, and B1 are as defined as set forth in the specification. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing a condition or disorder responsive to the degradation of CBP/P300 proteins (e.g., cancer).
    Type: Application
    Filed: March 3, 2022
    Publication date: May 9, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Mi Wang
  • Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors
    Patent number: 11944614
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, and R4 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 2, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Rohan Rej
  • Cereblon Ligands and Uses Thereof
    Publication number: 20240059704
    Abstract: Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: July 12, 2023
    Publication date: February 22, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Ranjan Kumar Acharyya, Weiguo Xiang, Rohan Rej, Longchuan Bai, Xuqing Zhang, Guozhang Xu